ImmuCell (ICCC) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmuCell is the larger company by market cap ($88.0 million vs $2.8 million), about 31.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ICCC | VRAX |
|---|---|---|
| Share price | $9.69 | $2.11 |
| Market cap | $88.01M | $2.84M |
| 1-day change | -2.81% | +3.94% |
| YTD return | +57.56% | — |
| 1-year return | +50.23% | — |
| 5-year return | +4.42% | — |
| P/E ratio (TTM) | 138.43 | — |
| EPS (TTM) | $0.07 | $-13.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.10 | $21.75 |
| 52-week low | $4.52 | $1.83 |
| Distance from 52-week high | -19.92% | -90.30% |
| Average volume | 23.16K | 1.80M |
| Shares outstanding | 9.08M | 1.34M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ImmuCell is about 31.0 times larger than Virax Biolabs Group by market value ($88.01M vs $2.84M).
ICCC vs VRAX FAQ
Which is bigger, ImmuCell or Virax Biolabs Group?
ImmuCell (ICCC) is larger, with a market capitalization of $88.01M compared with $2.84M for Virax Biolabs Group (VRAX).
Are ImmuCell and Virax Biolabs Group in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.